Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis

被引:9
|
作者
Nardelli, Silvia [1 ,7 ]
Riggio, Oliviero [1 ]
Marra, Fabio [2 ]
Gioia, Stefania [1 ]
Saltini, Dario [3 ]
Bellafante, Daniele [1 ]
Adotti, Valentina [2 ]
Guasconi, Tomas [3 ]
Ridola, Lorenzo [1 ]
Rosi, Martina [2 ]
Caporali, Cristian [4 ]
Fanelli, Fabrizio [5 ]
Roccarina, Davide [2 ]
Bianchini, Marcello [3 ]
Indulti, Federica [3 ]
Spagnoli, Alessandra [6 ]
Merli, Manuela [1 ]
Vizzutti, Francesco [2 ]
Schepis, Filippo [3 ]
机构
[1] Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy
[2] Univ Florence, Dept Expt & Clin Med, Florence, Italy
[3] Univ Modena & Reggio Emilia, Modena Hosp, Div Gastroenterol, Modena, Italy
[4] Univ Modena & Reggio Emilia, Modena Hosp, Dept Radiol, Modena, Italy
[5] Azienda Osped Univ Careggi, Intervent Radiol Unit, Florence, Italy
[6] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy
[7] Sapienza Univ Rome, Gastroenterol, Viale Univ 37, I-00161 Rome, Italy
关键词
overt hepatic encephalopathy; TIPS; liver cirrhosis; portal hypertension; STAGE LIVER-DISEASE; REFRACTORY ASCITES; FREE SURVIVAL; RISK-FACTORS; TIPS; POLYTETRAFLUOROETHYLENE; MODEL; MANAGEMENT; FAILURE; PATENCY;
D O I
10.1016/j.jhep.2023.11.033
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Overt hepatic encephalopathy (OHE) is a major complication of transjugular intrahepatic portosystemic shunt (TIPS) placement, given its high incidence and possibility of refractoriness to medical treatment. Nevertheless, the impact of post -TIPS OHE on mortality has not been investigated in a large population. Methods: We designed a multicenter, non -inferiority, observational study to evaluate the mortality rate at 30 months in patients with and without OHE after TIPS. We analyzed a database of 614 patients who underwent TIPS in three Italian centers and estimated the cumulative incidence of OHE and mortality with competitive risk analyses, setting the non -inferiority limit at 0.12. Results: During a median follow-up of 30 months (IQR 12-30), 293 patients developed at least one episode of OHE. Twenty-seven (9.2%) of them experienced recurrent/persistent OHE. Patients with OHE were older (64 [57-71] vs. 59 [50-67] years, p <0.001), had lower albumin (3.1 [2.8-3.5] vs. 3.25 [2.9-3.6] g/dl, p = 0.023), and had a higher prevalence of pre -TIPS OHE (15.4% vs. 9.0%, p = 0.023). Child -Pugh and MELD scores were similar. The 30 -month difference in mortality between patients with and without post -TIPS OHE was 0.03 (95% CI -0.042 to 0.102). Multivariable analysis showed that age (subdistribution hazard ratio 1.04, 95% CI 1.02-1.05, p <0.001) and MELD score (subdistribution hazard ratio 1.09, 95% CI 1.05-1.13, p <0.001), but not post -TIPS OHE, were associated with a higher mortality rate. Similar results were obtained when patients undergoing TIPS for variceal re -bleeding prophylaxis (n = 356) or refractory ascites (n = 258) were analyzed separately. The proportion of patients with persistent OHE after TIPS was significantly higher in the group of patients who died. The robustness of these results was increased following propensity score matching. Conclusion: Episodic OHE after TIPS is not associated with mortality in patients undergoing TIPS, regardless of the indication. (c) 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:596 / 602
页数:8
相关论文
共 50 条
  • [1] EPISODIC OVERT HEPATIC ENCEPHALOPATHY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT DOES NOT INCREASE MORTALITY IN PATIENTS WITH CIRRHOSIS
    Nardelli, S.
    Riggio, O.
    Marra, F.
    Gioia, S.
    Saltini, D.
    Bellafante, D.
    Adotti, V.
    Guasconi, T.
    Ridola, L.
    Rosi, M.
    Caporali, C.
    Fanelli, F.
    Roccarina, D.
    Bianchini, M.
    Indulti, F.
    Spagnoli, A.
    Merli, M.
    Vizzutti, F.
    Schepis, F.
    [J]. DIGESTIVE AND LIVER DISEASE, 2024, 56 : S110 - S110
  • [2] Risk factors for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation in patients with liver cirrhosis
    Tong, Huan
    Gan, Can
    Wei, Bo
    Wang, Zhi Dong
    Li, Xiao Dan
    Qian, Shuai Jie
    Huan, Hui
    Zhang, Lin Hao
    Yang, Zhu
    Chen, Yi Long
    Gu, Yong Hong
    Chen, Liu Xiang
    Yang, Yu Hang
    Wu, Hao
    Tang, Cheng Wei
    [J]. JOURNAL OF DIGESTIVE DISEASES, 2021, 22 (01) : 31 - 40
  • [3] RISK FACTORS FOR OVERT HEPATIC ENCEPHALOPATHY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT CREATION IN LIVER CIRRHOSIS PATIENTS
    Tong, Huan
    Wei, Bo
    Wu, Hao
    Tang, Chengwei
    [J]. HEPATOLOGY, 2019, 70 : 255A - 255A
  • [4] Early recurrent overt hepatic encephalopathy is associated with poor survival in patients with cirrhosis after transjugular intrahepatic portosystemic shunt
    Zuo, L.
    Chen, H.
    Wang, Q.
    He, C.
    Yin, Z.
    Tie, J.
    Wang, Z.
    Nie, Y.
    Han, G.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S371 - S371
  • [5] Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients
    Gou, Xiaoyuan
    Jia, Wenyuan
    He, Chuangye
    Yuan, Xulong
    Niu, Jing
    Xu, Jiao
    Han, Na
    Zhu, Ying
    Wang, Wenlan
    Tie, Jun
    [J]. EUROPEAN RADIOLOGY, 2023, 33 (05) : 3407 - 3415
  • [6] Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients
    Xiaoyuan Gou
    Wenyuan Jia
    Chuangye He
    Xulong Yuan
    Jing Niu
    Jiao Xu
    Na Han
    Ying Zhu
    Wenlan Wang
    Jun Tie
    [J]. European Radiology, 2023, 33 : 3407 - 3415
  • [7] Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt
    Mamiya, Y
    Kanazawa, H
    Kimura, Y
    Narahara, Y
    Yamate, Y
    Nakatsuka, K
    Sakamoto, C
    [J]. HEPATOLOGY RESEARCH, 2004, 30 (03) : 162 - 168
  • [8] Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt
    Riggio, Oliviero
    Nardelli, Silvia
    Moscucci, Federica
    Pasquale, Chiara
    Ridola, Lorenzo
    Merli, Manuela
    [J]. CLINICS IN LIVER DISEASE, 2012, 16 (01) : 133 - +
  • [9] In patients having transjugular intrahepatic portosystemic shunt, rifaximin prevented overt hepatic encephalopathy
    Koretz, Ronald L.
    [J]. ANNALS OF INTERNAL MEDICINE, 2021, 174 (07) : JC78 - JC78
  • [10] Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt
    Liang Yin
    Sen-Lin Chu
    Wei-Fu Lv
    Chun-Ze Zhou
    Kai-Cai Liu
    Yi-Jiang Zhu
    Wen-Yue Zhang
    Cui-Xia Wang
    Yong-Hui Zhang
    Dong Lu
    De-Lei Cheng
    [J]. World Journal of Gastroenterology, 2023, (18) : 2875 - 2887